Robert Clarke, Ph.D., is Co-founder and CEO of Kinaset Therapeutics. He previously served as CEO at Pulmatrix Inc. (NASDAQ:PULM), a clinical-stage respiratory drug delivery company. During his tenure, Pulmatrix listed a successful IPO and raised over $140 million to support the company’s development programs. Dr. Clarke holds Board seats at several institutions including EnBiotix, Johns Hopkins University and Boston University College of Engineering. Dr. Clarke earned his Ph.D. in physiology at Johns Hopkins University and completed his post-doctoral training in respiratory biology at Brigham and Women’s Hospital and Harvard University.
.svg)
